AC Immune (ACIU) Liabilities and Shareholders Equity (2014 - 2026)
AC Immune (ACIU) recorded Liabilities and Shareholders Equity of $190.29 million in the quarter ended Jun 30, 2026, down 17.2% from $229.77 million a year earlier but up 8.4% from the prior quarter.
Powered by 
Analysis
AC Immune (ACIU) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
As of Dec 31, 2025, AC Immune reported Liabilities and Shareholders Equity of $186.05 million, down 29.1% from the prior year.
- Annual Liabilities and Shareholders Equity has a five-year compound annual growth rate of -6.1% (years ended Dec 2020 to Dec 2025).
- Across earlier years, Liabilities and Shareholders Equity came in at $262.48 million in the year ended Dec 31, 2024 (+28.9%), $203.55 million in the year ended Dec 31, 2023 (+4.4%), $194.92 million in the year ended Dec 31, 2022 (-31.9%) and $286.11 million in the year ended Dec 31, 2021 (+12.4%).
- Quarterly Liabilities and Shareholders Equity has ranged from $161.88 million in the quarter ended Sep 30, 2023 to $283.54 million in the quarter ended Dec 31, 2021 over the past five years.
- On a year-over-year basis, Liabilities and Shareholders Equity has declined for five consecutive quarters, with growth averaging 2.4% over the last eight quarters.
- Peak year-over-year performance for Liabilities and Shareholders Equity in the last five years was growth of 74.1% in the quarter ended Sep 30, 2024, against a decline of 31.9% in the quarter ended Dec 31, 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $175.49 million (quarter ended Mar 31, 2026), $192.99 million (quarter ended Dec 31, 2025) and $214.53 million (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | AC Immune | 266.56 Mn | 266.56 Mn | - | 190.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 190.29 Mn |
| Mar 31, 2026 | 175.49 Mn |
| Dec 31, 2025 | 192.99 Mn |
| Sep 30, 2025 | 214.53 Mn |
| Jun 30, 2025 | 229.77 Mn |
| Mar 31, 2025 | 234.78 Mn |
| Dec 31, 2024 | 263.59 Mn |
| Sep 30, 2024 | 281.91 Mn |
| Jun 30, 2024 | 262.66 Mn |
| Mar 31, 2024 | 191.65 Mn |
| Dec 31, 2023 | 206.10 Mn |
| Sep 30, 2023 | 161.88 Mn |
| Jun 30, 2023 | 173.75 Mn |
| Mar 31, 2023 | 182.88 Mn |
| Dec 31, 2022 | 193.01 Mn |
| Sep 30, 2022 | 212.85 Mn |
| Jun 30, 2022 | 225.09 Mn |
| Mar 31, 2022 | 255.02 Mn |
| Dec 31, 2021 | 283.54 Mn |
| Sep 30, 2021 | 221.52 Mn |
API Access
AC Immune Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ACIU&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "ACIU", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ACIU&period=max&api_key=YOUR_API_KEY");
const data = await res.json();